| The influence of nutrition on intestinal permeability and the microbiome in health and disease O Inczefi, P Bacsur, T Resál, C Keresztes, T Molnár Frontiers in Nutrition 9, 718710, 2022 | 30 | 2022 |
| Iron deficiency anemia in inflammatory bowel disease: what do we know? T Resál, K Farkas, T Molnár Frontiers in Medicine 8, 686778, 2021 | 17 | 2021 |
| Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease–a prospective, multicentre study L Lontai, L Gonczi, F Balogh, N Komlodi, T Resal, K Farkas, T Molnar, ... Digestive and Liver Disease 54 (12), 1639-1645, 2022 | 9 | 2022 |
| Ciclosporin and vedolizumab for steroid-refractory ulcerative colitis T Resál, D Pigniczki, KJ Szántó, M Rutka, K Farkas, T Molnar Alimentary Pharmacology & Therapeutics 52 (3), 578-579, 2020 | 5 | 2020 |
| Endoscopic ultrasound in the lower gastrointestinal tract A Fábián, R Bor, Z Bősze, T Tóth, P Bacsur, A Bálint, K Farkas, T Resál, ... Orvosi Hetilap 164 (30), 1176-1186, 2023 | 4 | 2023 |
| The complex relationship between viruses and inflammatory bowel disease–review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic K Farkas, D Pigniczki, M Rutka, KJ Szántó, T Resál, R Bor, A Fábián, ... Therapeutic Advances in Gastroenterology 14, 1756284820988198, 2021 | 4 | 2021 |
| Real-life efficacy of tofacitinib in various situations in ulcerative colitis: a retrospective worldwide multicenter collaborative study T Resál, P Bacsur, C Keresztes, A Bálint, R Bor, A Fábián, B Farkas, ... Inflammatory Bowel Diseases 30 (5), 768-779, 2024 | 3 | 2024 |
| Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease … P Bacsur, M Matuz, T Resál, P Miheller, T Szamosi, E Schäfer, P Sarlós, ... Therapeutic Advances in Gastroenterology 15, 17562848221144349, 2022 | 3 | 2022 |
| P459 Expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in inflammatory bowel disease B Jójárt, T Molnár, V Szabó, Á Varga, T Resál, K Szántó, D Kata, I Földesi, ... Journal of Crohn's and Colitis 15 (Supplement_1), S453-S453, 2021 | 3 | 2021 |
| Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease P Ellul, J Schembri, A Vella Baldacchino, T Molnár, T Resal, M Allocca, ... Journal of Crohn's and Colitis 17 (4), 489-496, 2023 | 2 | 2023 |
| Infection risk related to gastrointestinal endoscopic procedures during the SARS-CoV-2 pandemic A Fábián, R Bor, T Tóth, P Bacsur, A Bálint, K Farkas, Á Milassin, T Molnár, ... Orvosi hetilap 163 (46), 1814-1822, 2022 | 2 | 2022 |
| Disease modelling of Inflammatory Bowel Disease by human colon organoids T Molnár, B Jójárt, T Resál, K Szántó, D Kata, I Földesi, T Molnár, J Maléth, ... JOURNAL OF CROHNS & COLITIS 15, S155-S155, 2021 | 2 | 2021 |
| Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases B Jójárt, T Resál, D Kata, T Molnár, P Bacsur, V Szabó, Á Varga, ... Journal of Crohn's & Colitis 18 (3), 392, 2024 | 1 | 2024 |
| Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary P Bacsur, Á Iliás, T Resál, D Kata, T Molnár, K Farkas Alimentary Pharmacology & Therapeutics 58 (2), 262-263, 2023 | 1 | 2023 |
| Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls P Bacsur, M Rutka, A Asbóth, T Resál, K Szántó, B Jójárt, A Bálint, E Ari, ... Therapeutic Advances in Gastroenterology 16, 17562848231174298, 2023 | 1 | 2023 |
| P578 Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients–a multicentre study on efficacy … L Lontai, L Gonczi, F Balogh, N Komlodi, T Resal, K Farkas, T Molnar, ... Journal of Crohn's and Colitis 16 (Supplement_1), i518-i519, 2022 | 1 | 2022 |
| P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort K Farkas, M Matuz, D Kata, I Földesi, T Resál, P Bacsur, K Szántó, ... Journal of Crohn's and Colitis 16 (Supplement_1), i425-i425, 2022 | 1 | 2022 |
| Appendiceal mucinous neoplasm appearance on NBI colonoscopy P Bacsur, T Resál, K Farkas, S Ábrahám, T Molnár Journal of Gastrointestinal and Liver Diseases 31 (3), 270-270, 2022 | 1 | 2022 |
| Still the Joker in the Pack: When to Take Out Cyclosporine in the Game? T Resál, K Szanto, M Rutka, K Farkas, T Molnar Inflammatory Bowel Diseases 27 (8), e95-e95, 2021 | 1 | 2021 |
| Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey T Resál, R Bor, K Szanto, A Fábián, M Rutka, M Sacco, DG Ribaldone, ... Therapeutic advances in gastroenterology 14, 17562848211006678, 2021 | 1 | 2021 |
